Q&A: What's Ahead for Biosimilar Litigation and the 'Patent Dance'

, The Recorder

   | 0 Comments

Goodwin Procter partner Elaine Herrmann Blais discusses the biologics case that's expected to reach the Supreme Court and why a repeal of the Affordable Care Act could have unwelcome ripple effects.

This premium content is reserved for CC Corporate Counsel subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202775026674

Thank you!

This article's comments will be reviewed.